Status:
COMPLETED
Budesonide Treatment for Lymphocytic Colitis
Lead Sponsor:
Technische Universität Dresden
Collaborating Sponsors:
Dr. Falk Pharma GmbH
Conditions:
Microscopic Colitis
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether orale budesonide is effective in the treatment of lymphocytic colitis
Detailed Description
The purpose of this study is to determine whether orale budesonide is effective in the treatment of lymphocytic colitis
Eligibility Criteria
Inclusion
- lymphocytic colitis
- diarrhea
- effective contraception
- written informed consent
Exclusion
- other forms if IBD
- celiac disease
- infectious colitis
- history of colonic surgery
- use of budesonide, 5-ASA, steroids within th previous 4 weeks
- pregnancy, lactation
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2007
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00180050
Start Date
January 1 2002
End Date
August 1 2007
Last Update
March 30 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Department I, Technical University Hospital
Dresden, Germany, 01307